S-531011 / Shionogi  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
S-531011 / Shionogi
aCCeleR8-001, NCT05101070: S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

Recruiting
1/2
274
Japan, US
S-531011, pembrolizumab, KEYTRUDA®
Shionogi, Merck Sharp & Dohme LLC
Solid Tumors
04/27
04/27

Download Options